This compound is an active pharmaceutical ingredient impurity, specifically an ethyl ester derivative of a quinoline-based structure. It is referenced as a reference standard for quality control in pharmaceutical manufacturing.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing this compound?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
N-(4-Methylbenzene-1-sulfonyl)-N-(prop-2-en-1-yl)benzenecarbohydrazonic acid
pharmaceutical raw material
Ethyl (E)-3,5-dihydroxy-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-hept-6-enoate
pharmaceutical raw material
Rifamycin sodium
pharmaceutical raw material
Butylscopolamine bromide
pharmaceutical raw material
(+)-norepinephrine
pharmaceutical raw material
Dexrazoxane hydrochloride
pharmaceutical raw material
Tert-Buthyl Pitavastatin
pharmaceutical raw material
(3R,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl)-3-hydroxy-5-oxo-6-heptenoic acid
pharmaceutical raw material
ethyl (E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-5-hydroxy-3-oxohept-6-enoate
DPBQVLWVWXLRGW-BUHFOSPRSA-N
CCOC(=O)CC(=O)CC(/C=C/C1=C(C2=CC=CC=C2N=C1C3CC3)C4=CC=C(C=C4)F)O
—
Sourcing this compound?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.